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Sodium lauryl sulfate [SLS; synonym: sodium dodecyl sulfate
(SDS) or C12H25NaO4S] is a surfactant that is used in many
household and hygiene products. It has an irritating effect on
skin and is therefore used extensively in models for testing the
response of skin to irritants. Already in 1997 the European
guideline on SLS exposure testing stated that ‘skin penetration
of SLS is expected to show a significant inter-individual and
anatomical site variation’. Furthermore, the flexor side forearm
skin (with cubital fossa and the wrist excluded) was recom-
mended as a preferred study site.1 Hereafter, several studies
that involved SLS testing have nonetheless used the back as the
anatomical test location, probably mostly because of its larger
area.2–4 This prompted studies that aimed to prospectively
assess whether there indeed was a difference in response to
irritation between anatomical locations. These studies showed
conflicting results,5–8 although the study by Lavrijsen et al.,
which showed no difference, probably had an insufficient
sample size.6
In this issue of the BJD, Leskur et al. present a randomized
controlled trial in which they aimed to investigate the
response of two anatomical locations, the volar forearm and
the upper back (subscapular area), to SLS-induced irritation
in vivo using a one-time occlusive test.9 They set the number
of participants at 25 to increase statistical power compared
with earlier studies. The irritation was induced to provoke an
acute reaction in healthy individuals and was compared with
sham irritation using distilled water.1 Concomitantly, the
effect of an emollient cream on recovery of the irritation was
tested.
The study shows that the upper back is more susceptible
than the volar forearm to irritation by SLS, as measured by
transepidermal water loss (TEWL), erythema and dryness. Fur-
thermore, recovery from irritation also seems dependent on
anatomical location, with the upper back recovering faster
than the volar forearm (adjusted for the initial difference in
irritation), confirming what was most often found in previous
studies.5,7,8 Baseline pre-irritation TEWL values were compara-
ble between the forearm and upper back. These values were
clearly not suitable predictors for the varying skin response,
which implies that there must be factors other than the barrier
function of the stratum corneum that contribute to the differ-
ence in response to irritation between anatomical locations.
This leads the authors to speculate that response to treatment
may also be anatomical site-specific, owing to structural skin
differences at various body locations.
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The emollient tested by Leskur et al. was given post-irrita-
tion to assess its effect on recovery.9 No effect on skin irri-
tation was seen when compared with sham-irritated skin.
Possibly, the reaction that was invoked using the one-time
occlusive test was too strong for treatment with an emol-
lient only.10 Also, the possible beneficial effect of pretreat-
ment (application of treatment before initiating the
irritation) or application using a repeated exposure model
(mimicking normal use of an emollient) was not assessed.
In previous years, multiple topical formulations have been
tested with SLS models, but anatomical location, method of
SLS exposure (one-time occlusion, repeated occlusion, open
test, immersion test) and/or SLS concentration often differ.
The study by Leskur et al. reinforces the notion that different
anatomical locations respond differently to irritation using
SLS. To improve comparability between studies, it is essen-
tial that researchers report anatomical test-site location and
carefully consider existing guidelines for standardization in
studies that involve SLS testing.
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In-transit metastases in stage III melanoma are usually treated
with (repeated) surgery and other locoregional treatments.
Talimogene laherparepvec (T-VEC) is a modified herpes sim-
plex virus type 1 and is given to patients with stage IIIb–
IVM1a melanoma with injectable cutaneous, subcutaneous or
lymph node metastases.1 This oncolytic virus stimulates viral
pathogenicity, enhances tumour-selective replication, and
reduces virally mediated suppression of antigen presentation
and thus induces tumour-specific T-cell responses.2–4 The first
real-world data of T-VEC monotherapy is promising, with
reported response rates varying from 56.5% up to 82.6%.5,6
A very elegant characteristic of T-VEC monotherapy is its rel-
atively mild side-effects. Patients often experience only self-lim-
iting flu-like symptoms such as fever, decreased appetite,
fatigue and local inconveniences such as itch, injection site pain
or erythema. This makes T-VEC monotherapy a considerably
less toxic alternative to systemic immunotherapies. For this rea-
son, it can be considered also for frail and elderly patients. Cur-
rently, the potential synergetic effect of T-VEC in combination
with immunotherapy is being investigated, studying pem-
brolizumab with T-VEC vs. pembrolizumab with placebo.7
This issue of the BJD includes an important case report
describing an 58-year-old organ transplant recipient who was
diagnosed with stage III melanoma with local progression of his
metastases after topical treatment with imiquimod and cryother-
apy.8 Organ transplant recipients are often not considered
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